Table 3.

Characteristics of studies included in the meta-analysis.

ArmID	StudyID	Study year	Country	Intervention	Dose	Design	Population	N	Any AE event	AE definition	Grade 3 plus AE event	InjSite AE event	Serious AE event	Follow up weeks
Arm1	LY01005_ RCT	2023	China	Microsphere	3.6mg	RCT	localized; locally advanced prostate cancer; Metastatic	144	117	TEAE	10	0	7	12
Arm2	LY01005_ RCT	2023	China	Implant	3.6mg	RCT	localized; locally advanced prostate cancer; Metastatic	145	124	TEAE	11	1	5	12
Arm3	GOS_ RWE_108	2024	China	Implant	10.8mg	Prospective cohort	localized; locally advanced prostate cancer	294	117	TEAE	31	NA	30	26
Arm4	ZOLA_ RCT	1995	Netherlands	Implant	10.8mg	RCT	advanced prostatic carcer	39	12	AE	NA	NA	NA	48
Arm5	ZOLA_ RCT	1995	Netherlands	Implant	3.6mg	RCT	advanced prostatic carcer	43	19	AE	NA	NA	NA	48

AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event; RCT, randomized controlled trial; NA, not available. The included studies used different methods and terminology for adverse event reporting. Gu et al. and Chen et al. reported treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), whereas Dijkman et al. did not explicitly describe the adverse event assessment criteria or reporting standard. Because adverse event definitions and reporting methods were not fully standardized across studies, pooled safety estimates should be interpreted with caution.